Immune myocarditis induced by camrelizumab
10.3760/cma.j.cn114015-20201019-01054
- VernacularTitle:卡瑞利珠单抗致免疫性心肌炎
- Author:
Ying SUN
1
;
Yongli GU
1
;
Guangsheng YANG
1
;
Zengxian SUN
1
Author Information
1. 南京医科大学康达学院第一附属医院药学部，连云港 222000
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents, immunological;
Cardiotoxicity;
Myocarditis;
Carelizumab
- From:
Adverse Drug Reactions Journal
2021;23(5):268-270
- CountryChina
- Language:Chinese
-
Abstract:
A 73-year-old male patient received immunotherapy (IV infusion of camrelizumab injection 200 mg once every 21 days) for mediastinal and right cervical lymph node metastasis after operation of esophageal cancer. Before immunotherapy, laboratory tests showed cardiac troponin I (cTnI) <0.01 μg/L, creatine kinase (CK) 69 U/L, and CK-MB 16 U/L. Electrocardiogram (ECG) showed no obvious abnormality. The day after the first IV infusion of camrelizumab, the patient developed fatigue, which were relieved without any treatment. The day after the second IV infusion of camrelizumab, he developed chest tightness, palpitation, and fatigue without obvious inducement. Laboratory tests showed cTnI 0.14 μg/L, CK 440 U/L, and CK-MB 39 U/L. ECG showed ST-T segment changes. Immune myocarditis due to camrelizumab was considered. An IV infusion of methylprednisolone injection (60-500 mg/d) was given. After 16 days of treatment, the patient′s chest tightness and palpitations were improved. Laboratory tests showed cTnI 0.48 μg/L, CK 94 U/L, and CK-MB 37 U/L.
